NCT07217678 - Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions

GlaucomaOpen-Angle GlaucomaOcular HypertensionGlaucoma Suspect

Interventions

DRUG

Durysta, Bimatoprost Intracameral Implant 10 µg

Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.

Trial Locations (1)

33134

Bascom Palmer Eye Institute, Miami